Match!
Elena Castro
Institute of Cancer Research
103Publications
15H-index
1,608Citations
Publications 105
Newest
We previously reported that the inactivation (cKO) or the stabilization (cST) of β-catenin in cells expressing the astrocyte-specific glutamate aspartate transporter (GLAST) is associated with the vulnerability or resilience to exhibit anxious/depressive-like behaviors, respectively, and to changes in hippocampal proliferation. Here, we used these cKO and cST β-catenin mice to study the serotonergic system functionality associated with their behavioral/molecular phenotype. The activity of 5-HT1A...
Source
#1Carlo CattriniH-Index: 4
#2Elena CastroH-Index: 15
Last.David OlmosH-Index: 38
view all 7 authors...
The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naive patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of pre...
Source
#1Elizabeth PageH-Index: 9
#2Elizabeth BancroftH-Index: 19
Last.Rosalind A. EelesH-Index: 93
view all 136 authors...
Abstract Background Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants Men aged 40–69 yr with a germline pathogenic BRC...
1 CitationsSource
#2Rebeca LozanoH-Index: 3
Last.Elena CastroH-Index: 15
view all 22 authors...
Abstract Early identification of germline BRCA1/2 mutations may be relevant for the management of patients with prostate cancer (PC) and to prevent future breast and ovarian cancers in their relatives. Several prediction tools have been developed to estimate the likelihood of a germline BRCA1/2 mutation and are widely used to optimize screening in breast and ovarian cancer patients. We aimed to elucidate the proportion of PC patients with known BRCA1/2 mutations who would have qualified for test...
Source
#1Vincenza Conteduca (UCL: University College London)H-Index: 27
#2Elena CastroH-Index: 15
Last.Ugo De GiorgiH-Index: 36
view all 24 authors...
Abstract Background Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status in the context of cabazitaxel therapy is unknown. Patients and methods Between September 2011 and January 2018, pretherapy plasma samples were collected from 155 patients treated w...
1 CitationsSource
#1Pasquale Rescigno (University of Naples Federico II)H-Index: 18
#2David Dolling (ICR: Institute of Cancer Research)H-Index: 11
Last.Johann S. de Bono (ICR: Institute of Cancer Research)H-Index: 97
view all 27 authors...
Abstract Background Declines in prostate-specific antigen (PSA) levels at 12 wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4 wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study. Objective To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. Design, setting, and p...
Source
#1María José Méndez-Vidal (Sofia University)H-Index: 5
#2Rebeca LozanoH-Index: 3
Last.David LorenteH-Index: 17
view all 20 authors...
5053Background: Abiraterone (Abi), enzalutamide (Enza) and docetaxel (Doc) are all valid first-line (1L) mCRPC treatment options. SIOG guidelines (Droz, Eur Urol 2017) recommend that fit elderly pt...
Source
e16530Background: Changes in PSA are widely used as a biomarker for the monitoring of treatment outcome in Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the clinical real-world setting...
Source
#1David LorenteH-Index: 17
#2Rebeca LozanoH-Index: 3
Last.David OlmosH-Index: 38
view all 10 authors...
e16541Background: PSA is a widely used biomarker for monitoring outcome in mCRPC. Current treatment guidelines do not consider PSA progression before at least 12 weeks of treatment, and recommend t...
Source
#1Enrique Grande (University of Texas MD Anderson Cancer Center)H-Index: 18
view all 20 authors...
5040Background: TMPRSS2-ERG fusion gene is a common driver of prostate cancer. The PREMIERE study is a phase II, single arm open-label, multicentre, clinical trial designed to analyse the predictiv...
Source
12345678910